Skip to main content
Premium Trial:

Request an Annual Quote

Anagnostics Taps Ramcon to Sell HybCell Array Platform in Nordic Region

Premium

Anagnostics said this week that Ramcon will sell its HybCell tests to customers in Denmark, Finland, Iceland, Norway, and Sweden.

Specifically, Ramcon will offer Anagnostics' drugs of abuse tests. The immunochemical assays rely on urine or saliva samples to semi-quantitatively test for drugs of abuse and psychotropic substances using the firm's cylindrical HybCell array platform. Ramcon will also sell Anagnostics' recently launched compact-sequencing-based pharmacogenetics tests (BAN 10/26/2010).

Anagnostics has expanded its reach via similar partnerships. The St. Valentin, Austria-based firm has inked deals with Cell.Eng to represent it in Italy, Invicon to sell its products in Germany, and Biogenetix to represent it in the Romanian market.

Birkerød-based Ramcon employs 24 sales support and service personnel. The company represents other players in the array market, including French scanner firm Innopsys, Italian biochip maker Silicon Biosystems, and Affymetrix's Panomics business.

Further details of the deal were not discussed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.